长期的骨密度变化和骨折风险在严重骨髓灰质炎:影响FRAX®工具应用程序
Shingo Konno1, Takafumi Uchi1, Hideo Kihara1
1Department of Neurology, Toho University Ohashi Medical Center, Tokyo 153-8515, Japan.
Healthcare (Basel, Switzerland)
|September 14, 2024
概括
长期服用葡萄糖皮质类药物的严重肌症患者面临重大骨折风险. 早期的骨密度查和FRAX®评估对于治疗骨质疏松症和预防骨折至关重要.
科学领域:
- 神经学 神经学
- 内分泌学 在内分泌学.
- 骨的新陈代谢 骨的新陈代谢
背景情况:
- 骨髓灰质炎 (MG) 需要长期的葡萄糖皮质体治疗.
- 已知葡萄糖皮质类药物会对骨健康产生负面影响.
- 在MG患者中,长期的骨健康结果尚未得到充分证实.
研究的目的:
- 为了评估MG患者的长期骨矿物质密度 (BMD) 变化.
- 为了确定10年内骨质疏松性骨折的发生率.
- 探索MG特定因素与骨健康之间的关联.
主要方法:
- 对28名MG患者进行了长达10年的前性队列研究.
- 基线评估BMD,T-score,Z-score和骨周转标记.
- 根据葡萄糖皮质激素剂量计算和调整的FRAX®得分;骨折监测.
主要成果:
- 17.9%的患者经历了严重的骨质疏松性骨折.
- 骨折组的基线BMD/T得分较低,FRAX®得分较高.
- 在随访期间,骨折组从骨质疏松症进展到骨质疏松症.
结论:
- 在MG患者的长期葡萄糖皮质类药物治疗中,骨质疏松性骨折的风险很大.
- 早期和定期的骨健康评估,包括FRAX®,对于风险分层至关重要.
- 这些发现支持主动管理策略,以减轻MG患者骨折风险.
关键词:
骨矿物质密度 骨矿物质密度骨折风险评估工具 (FRAX®) 的使用葡萄糖皮质类药物肌痛性骨髓灰质炎 (Myasthenia Gravis) 是一个严重的疾病.骨质疏松症是一种骨质疏松症.骨质疏松性骨折 骨质疏松性骨折更多相关视频
07:56Scanning Skeletal Remains for Bone Mineral Density in Forensic Contexts
Published on: January 29, 2018
17.5K
07:12Semiautomated Longitudinal Microcomputed Tomography-based Quantitative Structural Analysis of a Nude Rat Osteoporosis-related Vertebral Fracture Model
Published on: September 28, 2017
8.1K
相关概念视频
Bone Disorders
3.4K
Aging and its effect on bone remodeling is the most common cause of bone disorders. In young and healthy people, bone deposition and resorption happen at an equal rate to maintain optimal bone health.
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
3.4K
Myasthenia Gravis: Diagnostic Tests
699
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
699
Myasthenia Gravis: Overview and Treatment
1.3K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.3K
